Additionally, we aim to draw comparative features between ALKBH5 and FTO for their binding specificity, efficiency, and selectivity along with providing the recent updates of the various regulatory aspects of m6A erasers and the promising inhibitors to further guide the development of efficacious therapeutics to target cancers, metabolic disorders, and viruses. The gene discussed is ALKBH5; the disease is cancer.